Key Decisions and Approvals
The Board meeting, which commenced at 03:30 PM and concluded at 05:00 PM, considered and approved the following:
1. Unaudited Financial Results: Approved and took on record the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026.
2. Postal Ballot Notice: Approved the draft notice of a Postal Ballot to seek shareholder consent for the re-appointment of Mr. Neeraj Golas as an Independent Director.
3. Director Re-appointment: Approved the re-appointment of Mr. Neeraj Golas as an Independent Director for a period of 3 consecutive years, commencing from 16th January 2027, subject to shareholder approval.
Standalone Financial Performance (in lakhs)
Quarter Ended 30th Sept 2026 (Q2 FY27):
- Revenue from Operations: ₹4,419.95
- Other Income: ₹58.96
- Total Income: ₹4,478.91
- Profit Before Tax: ₹111.76
- Net Profit After Tax: ₹131.50
- Basic & Diluted EPS: ₹0.36 (not annualized)
Quarter Ended 30th Sept 2025 (Q2 FY26):
- Revenue from Operations: ₹3,297.03
- Net Loss After Tax: ₹(362.07)
- Basic & Diluted EPS: ₹(1.01)
Half Year Ended 30th Sept 2026 (H1 FY27):
- Revenue from Operations: ₹8,650.89
- Net Profit After Tax: ₹341.53
- Basic & Diluted EPS: ₹0.94
Half Year Ended 30th Sept 2025 (H1 FY26):
- Revenue from Operations: ₹6,214.67
- Net Loss After Tax: ₹(280.99)
- Basic & Diluted EPS: ₹(0.78)
Year Ended 31st Mar 2026 (FY26 Audited):
- Revenue from Operations: ₹12,090.53
- Net Loss After Tax: ₹(3,228.84)
- Basic & Diluted EPS: ₹(8.93)
Consolidated Financial Performance (in lakhs)
Quarter Ended 30th Sept 2026 (Q2 FY27):
- Revenue from Operations: ₹4,419.95
- Net Profit After Tax: ₹127.11
- Profit attributable to owners of the parent: ₹128.63
- Basic & Diluted EPS: ₹0.36
Half Year Ended 30th Sept 2026 (H1 FY27):
- Revenue from Operations: ₹8,650.89
- Net Profit After Tax: ₹331.77
- Profit attributable to owners of the parent: ₹335.15
- Basic & Diluted EPS: ₹0.93
Key Balance Sheet Items (Standalone as at 30th Sept 2026)
- Total Assets: ₹17,879.58 lakh
- Total Equity: ₹9,041.44 lakh
- Paid-up Equity Share Capital: ₹3,615.27 lakh (FV ₹10/- each)
- Borrowings (Non-Current + Current): ₹4,431.06 lakh
Cash Flow Statement (Standalone H1 FY27)
- Net Cash from Operating Activities: ₹1,265.64 lakh
- Net Cash used in Investing Activities: ₹(623.10) lakh
- Net Cash used in Financing Activities: ₹(642.73) lakh
- Net decrease in Cash: ₹(0.18) lakh
Subsidiary Information
The consolidated results include the following entities:
- Lyka Labs Limited (Parent)
- Lyka BDR International Limited (Subsidiary)
The subsidiary contributed a net loss of ₹(4.37) lakh for the quarter and ₹(9.73) lakh for the half year.
Auditor's Review
D. Kothary & Co., Chartered Accountants, issued an unqualified review conclusion on both the standalone and consolidated unaudited financial results for the quarter and half year ended 30th September 2026.
Notes to Accounts
1. The financial results were approved by the Audit Committee and Board of Directors on 30th October 2026.
2. The figures reflect the accounting impact of the NCLT-sanctioned Scheme of Amalgamation for the merger of Lyka Export Limited with Lyka Labs Limited. The order was dated 16th March 2026, and accounting is effective from the date required under Ind AS 103.
3. The Company operates in one business segment: Pharmaceuticals.
4. Previous year figures have been restated/rearranged where necessary.
Director Re-appointment Details (Annexure-2)
- Name: Mr. Neeraj Golas
- DIN: 06566069
- Nature of Change: Re-appointment
- Proposed Term: 3 consecutive years from 16th January 2027
- Profile: Practicing Chartered Accountant with over 30 years of experience in Audit, Accounting, and Finance.
- Relationship: Not related to any other Directors or Key Managerial Personnel.
- Other Directorships: Holds no directorships in other listed entities.
- Compliance: Affirmed that he is not debarred from holding the office of Director by any SEBI order or statutory authority.